| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/18/2003 | WO2002095704A8 Use of nf-kappa-b inhibitors to treat dry eye disorders |
| 09/18/2003 | WO2002077267A3 Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon |
| 09/18/2003 | WO2002072790A3 Tsg101-gag interaction and use thereof |
| 09/18/2003 | WO2002066646A3 Neurotransmission-associated proteins |
| 09/18/2003 | WO2002062750A9 Cannabinoid receptor ligands |
| 09/18/2003 | WO2002062391A3 Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea |
| 09/18/2003 | WO2002053177A3 Agents and methods for treating pain |
| 09/18/2003 | WO2002000687A9 Antimicrobial peptides and methods of use thereof |
| 09/18/2003 | US20030176661 Novel antibody with specificity for colon cancer |
| 09/18/2003 | US20030176651 Multiprotein-complex comprising a nmda receptor and uses thereof |
| 09/18/2003 | US20030176647 Antibodies to OCIF-binding molecules |
| 09/18/2003 | US20030176514 Method for preparing a mixture that can be granulated and carnitine-magnesium hydroxycitrate |
| 09/18/2003 | US20030176511 Compositions and methods for treating cardiovascular disorders |
| 09/18/2003 | US20030176505 Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| 09/18/2003 | US20030176504 Administering a therapeutically effective amount of an alpha2delta ligand other than gabapentin or tiagabine, or pharmaceutically acceptable salt thereof |
| 09/18/2003 | US20030176500 Medium chain fatty acids applicable as antimicrobial agents |
| 09/18/2003 | US20030176499 Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure |
| 09/18/2003 | US20030176496 Administering an antiproliferative agent in combination with a potentiating effective amount of a N- substituted dithiocarbamate ester or a pharmaceutically acceptable salt thereof |
| 09/18/2003 | US20030176495 HIV Integrase inhibitors |
| 09/18/2003 | US20030176484 Administering to the mammal an effective amount of a GSK-3 beta (glycogen synthase kinase-3 beta) to promote bone formation and treat bone metabolic diseases such as osteoporosis |
| 09/18/2003 | US20030176483 For therapy and prophylaxis of Herpes Simplex Virus and related diseases including secondary opportunist disease causing agents, while reducing the inflammation, prolonged healing times and reduce scaring |
| 09/18/2003 | US20030176465 Cyclic amino acid derivatives |
| 09/18/2003 | US20030176460 Piperidine compounds for use as ccr-3 inhibitors |
| 09/18/2003 | US20030176457 Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| 09/18/2003 | US20030176442 Administering cGMP PDE5 inhibitor for therapy of diabetic ulcers |
| 09/18/2003 | US20030176438 Useful as adjuvants to chemotherapy or radiation therapy in the treatment of cancer; as inhibitors of checkpoint kinase Cds1 (in man also known as Chk2) |
| 09/18/2003 | US20030176433 For therapy and prophylaxis of hepatitis C virus (HCV) infection |
| 09/18/2003 | US20030176420 Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists |
| 09/18/2003 | US20030176413 Polycyclic guanine derivative phosphodiesterase V inhibitors |
| 09/18/2003 | US20030176409 Administering a low dose of estrogen to mammal |
| 09/18/2003 | US20030176404 Progestogen-anti-progestogen regimens |
| 09/18/2003 | US20030176403 Combination chemotherapy |
| 09/18/2003 | US20030176397 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced GI toxicity |
| 09/18/2003 | US20030176392 Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes ("KHSV") |
| 09/18/2003 | US20030176388 Fatty acid synthase mRNA binding protein |
| 09/18/2003 | US20030176381 Hyaluronic acid in the treatment of cancer |
| 09/18/2003 | US20030176379 Useful in the administration of a drug, therapy |
| 09/18/2003 | US20030176365 To improve cerebral function |
| 09/18/2003 | US20030176364 Antimicrobial therapeutic compositions and methods of use |
| 09/18/2003 | US20030176360 For use in drugs used for therapy of prostate cancer, benign prostatic hyperplasia, endometriosis, hysteromyoma, metrofibroma, precocious puberty, breast cancer, and the like |
| 09/18/2003 | US20030176359 Administration of a thiol-based chemoprotectant compound |
| 09/18/2003 | US20030176346 Using substances that activate the CNTF (ciliary neurotrophic factor) receptor for the preparation of pharmaceutical formulations for therapy of obesity and diseases associated therewith, for example diabetes |
| 09/18/2003 | US20030176341 For use as an anti-viral, anti-tumour or immunomodulatory agent |
| 09/18/2003 | US20030176318 Administering a therapeutically effective amount of a temporary p53 inhibitor to an individual suffering from the disease or condition |
| 09/18/2003 | US20030176317 Stabilization of hypoxia inducible factor (HIF) alpha |
| 09/18/2003 | US20030176315 Contacting latency-associated peptide- beta 1 (LAP- beta 1) or a functional variant thereof and integrin alpha v beta 3 or a functional variant thereof with test product under conditions that, in absence of test product, would permit interaction |
| 09/18/2003 | US20030175962 Gene encoding b protein |
| 09/18/2003 | US20030175950 RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| 09/18/2003 | US20030175881 Nucleic acids encoding (poly) peptides having chips activity |
| 09/18/2003 | US20030175849 Identifying compounds for treating vision defects associated with intraocular pressure |
| 09/18/2003 | US20030175832 Diagnosing nervous system disorder via presence of aberrant macrophages in blood |
| 09/18/2003 | US20030175823 Method of screening remedy for heart failures |
| 09/18/2003 | US20030175822 Opiate, cannabinoid, and estrogen receptors |
| 09/18/2003 | US20030175775 Ligand for G-protein coupled receptor GPR43 and uses thereof |
| 09/18/2003 | US20030175766 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| 09/18/2003 | US20030175764 Monitoring interleukin allelic expression to detect occlusive, fragile plaque, restenosive and atherscerotic disorders |
| 09/18/2003 | US20030175753 Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling |
| 09/18/2003 | US20030175741 PCP-administered (phencyclidine/angel dust) chronic animal models; drug screening |
| 09/18/2003 | US20030175680 Methods of treating and preventing bone loss |
| 09/18/2003 | US20030175679 Detecting modulators of ubiquitin conjugating enzyme complex formation; drug screening |
| 09/18/2003 | US20030175362 Disinfecting nitrous acid compositions and process for using the same |
| 09/18/2003 | US20030175361 Using selenium in combination with drugs used conventionally to treat psychiatric or neurological disorders |
| 09/18/2003 | US20030175360 Comprising locally acting anesthetic, and an antacid; treatment of gastroesophageal reflux disease |
| 09/18/2003 | US20030175357 Prolonged anesthesia in joints and body spaces |
| 09/18/2003 | US20030175356 Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma |
| 09/18/2003 | US20030175348 Novel pharmaceutical formulation with controlled release of active substances |
| 09/18/2003 | US20030175344 Comprising diuretic, beta blocker, angiotensin converting enzyme inhibitor, angiotensin II receptor antagonist, calcium channel blocker, lipid-regulating agent, platelet function altering agent, serum homocysteine lowering agent |
| 09/18/2003 | US20030175340 Antiulcer agents (H2-antagonists such as ranitidine and cimetidine); for treating osteoporosis |
| 09/18/2003 | US20030175339 Formed by direct compression; friability |
| 09/18/2003 | US20030175334 Phospholipid bodies and use thereof in medical treatment |
| 09/18/2003 | US20030175333 Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin |
| 09/18/2003 | US20030175328 Patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients into the skin |
| 09/18/2003 | US20030175310 A pure immunogenic polypeptide for producing polyclonal and monoclonal antibodies |
| 09/18/2003 | US20030175307 Treating intestinal infections in a ruminant by administering a Lactobacillus acidophilus strain, able producing lactic acid; gastrointestinal disorders, veterinary medicine; increasing the fat content of milk produced by a dairy cow |
| 09/18/2003 | US20030175306 Treating intestinal infections in a ruminant by administering a Lactobacillus acidophilus strain, able producing lactic acid; gastrointestinal disorders, veterinary medicine; increasing the fat content of milk produced by a dairy cow |
| 09/18/2003 | US20030175289 TIE ligands |
| 09/18/2003 | US20030175282 Photodynamic therapy comprising administering angiogenesis factor antagonists and photosensitizers then irradiating with lasers, for prophylaxis of vision defects |
| 09/18/2003 | US20030175281 Monoclonal antibodies that preferntially bind to proteins having cytolysis and immunogenic activity |
| 09/18/2003 | US20030175280 Antagonists to chaperonin 10 |
| 09/18/2003 | US20030175279 Diagnosing and prophylaxis of tumors, endometriosis and fibroids, by administering Endometrial Steroid Binding Protein II (ESBPII) antagonists, then analyzing the polypeptide concentration in cells, tissues or fluids |
| 09/18/2003 | US20030175276 Monoclonal antibodies used as antagonists vascular endothelial growth factors (VEGF); angiogenesis inhibitors; antitumor agents |
| 09/18/2003 | US20030175274 Polynucleotides codes for antibodies having amino acid sequences selected from complementary determining regions of variable peptides or single chain fragments, used as anticarcinogenic agents |
| 09/18/2003 | US20030175271 VEGF activity inhibitor |
| 09/18/2003 | US20030175267 Method for the treatment of inflammatory joint disease |
| 09/18/2003 | US20030175261 Captopril; hyaluronidases; phospholipases |
| 09/18/2003 | US20030175259 Use of corneal hardening agents in enzymeorthokeratology |
| 09/18/2003 | US20030175252 Therapeutic compounds for ovarian cancer |
| 09/18/2003 | DE20121877U1 Module for suppressing leukocyte activity, useful e.g. in association with heart-lung machines, comprises a carrier linked to a ligand specific for the leukocyte receptor |
| 09/18/2003 | CA2813780A1 Genetic products differentially expressed in tumors and use thereof |
| 09/18/2003 | CA2479021A1 Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions |
| 09/18/2003 | CA2478958A1 Use of proton pump inhibitors for the treatment of airway disorders |
| 09/18/2003 | CA2478827A1 Remedies for sex hormone-dependent disease |
| 09/18/2003 | CA2478685A1 Ophthalmic solutions containing tetrazole derivatives |
| 09/18/2003 | CA2478604A1 Cancer-linked gene as target for chemotherapy |
| 09/18/2003 | CA2478599A1 Salts of nateglinide |
| 09/18/2003 | CA2478593A1 Cancer-linked gene as target for chemotherapy |
| 09/18/2003 | CA2478592A1 Genomic screen for epigenetically silenced genes associated with cancer |
| 09/18/2003 | CA2478522A1 Novel curcuminoid-factor viia constructs as suppressors of tumor growth and angiogenesis |
| 09/18/2003 | CA2478510A1 Genomic screen for epigenetically silenced tumor suppressor genes |
| 09/18/2003 | CA2478413A1 Genetic products differentially expressed in tumors and use thereof |